Replies to post #41070 on Biotech Values

[Dr Bill]

RPRX- ALSO Don't forget

that the market is just now remembering that we've got two drugs instead of one, and that androxal is likely a 20-30 Million dollar cash payment waiting to happen. The PR about the Androxal news : We anticipate completing this trial in the first half of 2007 and will provide our shareholders with an update on the final analysis when it is available." Mr. Podolski continued, "With these encouraging results in hand, we will seek to identify a licensing partner for Androxal in Europe." Now, if they get 30 Million from the offering, they sell the right to partner in Europe from Androxal for another 30 not mention milestone payments etc, they've then got $5+ per diluted share just in cash alone. That IMO makes this story one of the very best buys in biotech land, south of $40, right now.